Clinical trial
A Study to Evaluate the Persistence of Anti-HBs Antibodies at Months 12, 24 and 36 in Pre-dialysis or Dialysis Patients Who Have Received a Primary Vaccination Course of Either Henogen's HBV Vaccine, HB-AS02V or GSK Biological's Fendrix™
NCT00445185 is registered in ClinicalTrials.gov with Henogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Evaluate the Persistence of Anti-HBs Antibodies at Months 12, 24 and 36 in Pre-dialysis or Dialysis Patients Who Have Received a Primary Vaccination Course of Either Henogen's HBV Vaccine, HB-AS02V or GSK Biological's Fendrix™
- Lead sponsor
- Henogen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- November 30, 2009
- Enrollment
- 102 (estimated)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.